Cytokinetics achieved a major milestone in Q4 2025 with the FDA approval of MYQORZO for obstructive hypertrophic cardiomyopathy. While the company reported a net loss of $183 million for the quarter, it ended the year with a strong cash position of $1.22 billion to support its U.S. commercial launch and ongoing Phase 3 clinical trials.

Cytokinetics reported a net loss of $161.4 million for Q1 2025, with total revenues of $1.6 million. The company maintained a strong cash position of approximately $1.1 billion and continued to advance its clinical pipeline, including the extension of the PDUFA date for aficamten and completion of enrollment for ACACIA-HCM.

Cytokinetics' Q4 2024 revenue surged to $16.9 million, up from $1.7 million a year ago, primarily driven by a $15 million upfront payment from Corxel related to aficamten. However, research and development expenses rose to $93.6 million, reflecting the company's continued investment in clinical trials. Net loss widened to $150 million, translating to a GAAP EPS of -$1.26. The company ended the quarter with a strong cash position of $1.2 billion.

Cytokinetics reported a net loss of $143.3 million for the second quarter of 2024. The company had $1.4 billion in cash, cash equivalents and investments as of June 30, 2024.

Cytokinetics reported a net loss of $135.6 million for the first quarter of 2024, compared to a net loss of $131.3 million for the same period in 2023. The company's cash, cash equivalents, and investments totaled $634.3 million as of March 31, 2024. Key activities included advancing the aficamten development program, initiating enrollment in the CEDAR-HCM trial, and progressing CK-586 towards a Phase 2 clinical trial.

Cytokinetics reported a net loss of $136.9 million for Q4 2023. The company is preparing regulatory submissions for aficamten and advancing its clinical trials. They ended the year with $655.4 million in cash, cash equivalents and investments.

Cytokinetics reported its Q3 2023 financial results, highlighting progress in its specialty cardiology franchise, particularly with aficamten. The company is on track for topline results from the SEQUOIA-HCM trial in late December and has initiated enrollment in the ACACIA-HCM trial. The company's cash, cash equivalents and investments totaled $554.7 million on September 30, 2023.

Cytokinetics reported a net loss of $128.6 million for the second quarter of 2023. The company completed enrollment in the SEQUOIA-HCM trial and initiated enrollment in the MAPLE-HCM trial. They also reduced projected spending by approximately 15% and revised 2023 financial spending guidance.

Cytokinetics reported its Q1 2023 financial results, with a net loss of $131.3 million, or $1.38 per share. The company's cash, cash equivalents, and investments totaled $704.4 million as of March 31, 2023. They are reducing their spending to maintain over two years of cash runway.

Cytokinetics reported a net loss of $137.4 million for Q4 2022, compared to a net loss of $30.6 million in Q4 2021. The company highlighted the advancement of aficamten, the continuation of the COURAGE-ALS trial, and assessment of next steps for omecamtiv mecarbil.

Cytokinetics reported a net loss of $142.3 million, or $1.52 per share, for the third quarter of 2022. The company's cash, cash equivalents, and investments totaled $896.2 million at September 30, 2022.

Cytokinetics reported a net loss of $19.8 million for Q2 2022, with cash, cash equivalents, and investments totaling $596.7 million as of June 30, 2022. The company revised its 2022 financial guidance, anticipating operating expenses between $375 to $385 million and expects to end the year with over $800 million in cash.

Cytokinetics reported a net loss of $89.4 million, or $1.05 per share, for the first quarter of 2022. Cash, cash equivalents and investments totaled $686.1 million at March 31, 2022.

Cytokinetics reported a net loss of $30.6 million for Q4 2021, with revenues increasing to $55.6 million compared to $6.7 million in the same period of 2020, primarily driven by license revenue from Ji Xing. The company's cash balance reached $623.7 million at the end of the year, and they anticipate revenue between $20 to $25 million for 2022.

Cytokinetics reported a net loss of $76.1 million, or $0.95 per share, for the third quarter of 2021. Revenues for the quarter were $5.4 million. Cash, cash equivalents and investments totaled $668.9 million at September 30, 2021.

Cytokinetics reported a net loss of $61.6 million for the second quarter of 2021. The company is progressing with its late-stage muscle biology-directed pipeline and preparing for its first NDA submission. Following a recent financing, they have more than three years of cash runway.

Cytokinetics reported a net loss of $47.1 million, or $0.66 per share, for the first quarter of 2021. Revenues increased to $6.5 million from $3.8 million for the first quarter of 2020. Cash, cash equivalents and investments totaled $460.2 million at March 31, 2021.

Cytokinetics reported a net loss of $43.9 million for the fourth quarter of 2020, with revenues of $6.7 million. The company's cash, cash equivalents, and investments totaled $501.0 million at the end of the year, providing more than two years of cash runway.

Cytokinetics reported net loss of $3.2 million, or $0.05 per share, for the third quarter of 2020. Revenues increased to $41.7 million primarily due to license revenue from RTW transactions. The company's cash, cash equivalents, and investments totaled $451.2 million as of September 30, 2020.

Cytokinetics reported a net loss of $40.8 million, or $0.68 per share, for the second quarter of 2020. The company's cash, cash equivalents, and investments totaled $213.1 million at June 30, 2020. They expect to end the year with over $500 million in cash.